Screening for Urinary Incontinence by Primary Care Providers

Back to Search
Print
Bookmark Trial

NCT00178334

Last updated date
Back to Search
Print
Bookmark Trial
FOR MORE INFORMATION
Contact
1-800-718-1021
[email protected]
Related Links

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Urinary Incontinence
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
21 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- All primary care providers in the Greater Rochester metropolitan area, including: Primary care Medical Doctors (MD), Doctors of Osteopathy (DO), Primary care Nurse Practitioners (NP), and Physician Assistants (PA)

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Physicians in the Greater Rochester metropolitan area who are not primary care
providers

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

Call Now

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Advanced Search

Based on your search, you may also be interested in

Urinary IncontinenceA Comparison of Tolterodine and Placebo Treatments on Nocturnal Frequency and Sleep Quality in Women After Menopause.
NCT00323635
  1. Boston, Massachusetts
  2. Boston, Massachusetts
Female
45 Years+
years
MULTIPLE SITES
Urinary IncontinenceScreening for Urinary Incontinence by Primary Care Providers
NCT00178334
ALL GENDERS
21 Years+
years
MULTIPLE SITES
Urinary IncontinenceEvaluate Efficacy and Safety Of Tolterodine Extended Release Capsule Compared With Tolterodine Immediate Release Tablet
NCT00139724
  1. Beijing, Beijing
  2. Beijing, Beijing
  3. Huangzhou, Zhejiang
  4. Beijing,
  5. Chongqing,
  6. Shanghai,
  7. Shanghai,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Urinary IncontinenceEffect of Detrol LA on Overactive Bladder Symptoms, Sexual Quality of Life and Sexual Function in Women
NCT00143481
  1. Chandler, Arizona
  2. Phoenix, Arizona
  3. Little Rock, Arkansas
  4. Berkeley, California
  5. Oakland, California
  6. San Diego, California
  7. San Francisco, California
  8. Santa Rosa, California
  9. Denver, Colorado
  10. Denver, Colorado
  11. Lakewood, Colorado
  12. Farmington, Connecticut
  13. West Hartford, Connecticut
  14. Clearwater, Florida
  15. Leesburg, Florida
  16. Miami, Florida
  17. Pembroke Pines, Florida
  18. West Palm Beach, Florida
  19. Weston, Florida
  20. Alpharetta, Georgia
  21. Evansville, Indiana
  22. Newburgh, Indiana
  23. South Bend, Indiana
  24. Baton Rouge, Louisiana
  25. Metairie, Louisiana
  26. Metairie, Louisiana
  27. Baltimore, Maryland
  28. Saginaw, Michigan
  29. Creve Coeur, Missouri
  30. Las Vegas, Nevada
  31. Las Vegas, Nevada
  32. North Las Vegas, Nevada
  33. New Brunswick, New Jersey
  34. Albuquerque, New Mexico
  35. Olean, New York
  36. New Bern, North Carolina
  37. Winston-Salem, North Carolina
  38. Cincinnati, Ohio
  39. Cincinnati, Ohio
  40. Cleveland, Ohio
  41. Cleveland, Ohio
  42. Columbus, Ohio
  43. Gallipolis, Ohio
  44. Allentown, Pennsylvania
  45. Philadelphia, Pennsylvania
  46. Columbia, South Carolina
  47. Austin, Texas
  48. Austin, Texas
  49. Austin, Texas
  50. Bryan, Texas
  51. Conroe, Texas
  52. Irving, Texas
  53. San Antonio, Texas
  54. Salt Lake City, Utah
  55. Salt Lake City, Utah
  56. Seattle, Washington
  57. Morgantown, West Virginia
  58. Morgantown, West Virginia
Female
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title Screening for Urinary Incontinence by Primary Care Providers
Official Title Screening for Urinary Incontinence by Primary Care Providers
Brief Summary

The purpose of this study is to:

  • Assess the rate of screening for urinary incontinence (UI) in women by their primary care providers
  • Identify the type of screening used by primary care providers
  • Identify barriers to screening for UI
  • Identify differences in screening rates between specialties
  • Assess whether primary care providers view UI as a serious medical problem
  • Assess the comfort level of primary care providers in the diagnosis and treatment of UI
  • Identify primary care providers' preferred mode of learning more about UI
Detailed Description UI is a very common condition whose prevalence can be expected to increase dramatically in the coming decades. Treatment options are available to improve women's health and quality of life. However, inadequate communication between physicians and patients leads to decreased diagnosis and treatment. Past studies evaluating the use of screening by primary care providers, who act as gatekeepers in our healthcare system, clearly demonstrate that improvements must be made in the screening system. We propose a survey of local primary care providers to quantify screening rates for UI and identify barriers to successful screening. The information collected in this survey will allow us to identify methods such as targeted education opportunities and patient literature or questionnaires that will assist providers and their patients in initiating discussion and evaluation of UI.
Study Type Observational
Study Design Observational Model: Cohort
Time Perspective: Prospective
Target Follow-Up Duration Not Provided
Biospecimen Not Provided
Sampling Method Probability Sample
Study Population Primary care providers
Condition Urinary Incontinence
Intervention Not Provided
Study Groups/Cohorts Not Provided
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status Completed
Actual Enrollment
 (submitted: July 21, 2008)		554
Original Enrollment
 (submitted: September 12, 2005)		1500
Actual Study Completion Date July 2006
Actual Primary Completion Date July 2006   (Final data collection date for primary outcome measure)
Eligibility Criteria

Inclusion Criteria:

  • All primary care providers in the Greater Rochester metropolitan area, including: Primary care Medical Doctors (MD), Doctors of Osteopathy (DO), Primary care Nurse Practitioners (NP), and Physician Assistants (PA)

Exclusion Criteria:

  • Physicians in the Greater Rochester metropolitan area who are not primary care providers
Sex/Gender
Sexes Eligible for Study:All
Ages 21 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers Yes
Contacts Contact information is only displayed when the study is recruiting subjects
Listed Location Countries Not Provided
Removed Location Countries  
 
Administrative Information
NCT Number NCT00178334
Other Study ID Numbers 11355
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement Not Provided
Responsible Party Gunhilde Buchsbaum, University of Rochester
Study Sponsor University of Rochester
Collaborators Pfizer
Investigators
Principal Investigator:Gunhilde Buchsbaum, MDUniversity of Rochester
PRS Account University of Rochester
Verification Date January 2013